All clinically approved drugs targeting the plasmalemmal transporters for dopamine,
norepinephrine, and serotonin act either as competitive uptake inhibitors or as amphetamine-like …

Determining the structural elements that define substrates and inhibitors at the monoamine
transporters is critical to elucidating the mechanisms underlying these disparate functions. In …

The plasmalemmal monoamine transporters clear the extracellular space from their cognate
substrates and sustain cellular monoamine stores even during neuronal activity. In some …

The membrane transporters for the monoamines serotonin (SERT) and dopamine (DAT) are
prominent targets of various psychoactive substances, including competitive inhibitors, such …

Oscillatory neural dynamics are an inseparable part of mammalian sleep. Characteristic
rhythms are associated with different sleep stages and variable levels of sleep pressure, but it …

The dopamine transporter shapes dopaminergic neurotransmission by clearing extracellular
dopamine and by replenishing vesicular stores. The dopamine transporter carries an …

Point mutations in SLC6 transporters cause misfolding, which can be remedied by
pharmacochaperones. The serotonin transporter (SERT/SLC6A4) has a rich pharmacology including …

Controversy regarding the number and function of ligand binding sites in neurotransmitter/sodium
symporters arose from conflicting data in crystal structures and molecular …

… Bhat and PS Hasenhuetl analyzed the electrophysiological data. PS Hasenhuetl and W.
Sandtner designed the model. PS Hasenhuetl performed the simulations. FP Mayer and HH …

The human dopamine transporter (DAT) has a tetrahedral Zn 2+ -binding site. Zn 2+ -binding
sites are also recognized by other first-row transition metals. Excessive accumulation of …